

**MOTION SICKNESS ORIGINAL FORMULA- dimenhydrinate tablet
McKesson (Sunmark)**

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Drug Facts

Active ingredient (in each tablet)

Dimenhydrinate 50 mg

Purpose

Antiemetic

Uses

for the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.

Warnings

Do not use

for children under 2 years of age unless directed by a doctor.

Ask a doctor before use if you have

- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- difficulty in urination due to an enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

taking sedatives or tranquilizers.

When using this product

- marked drowsiness may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity

adults and children 12 years | 1 to 2 tablets every 4-6 hours; not to exceed 8 tablets in 24 hours, or as

and over	directed by a doctor
children 6 to under 12 years	1/2 to 1 tablet every 6-8 hours; not to exceed 3 tablets in 24 hours, or as directed by a doctor
children 2 to under 6 years	1/4 to 1/2 tablet every 6-8 hours; not to exceed 1-1/2 tablets in 24 hours, or as directed by a doctor

Other information

- each tablet contains: **calcium 30 mg**
- store at room temperature 20°-25°C (68°-77°F)

Inactive ingredients

croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

Questions or comments?

Call **1-877-753-3935 Monday-Friday 9AM-5PM EST**

Principal Display Panel

COMPARE TO DRAMAMINE® ORIGINAL FORMULA ACTIVE INGREDIENT*

Helps to prevent nausea, vomiting or dizziness associated with motion sickness

Motion Sickness

Original Formula

For children & adults

DIMENHYDRINATE

ANTIEMETIC

FAST ACTING

TABLETS 50 mg EACH

*This product is not manufactured or distributed by Prestige Brands, Inc., owner of the registered trademark Dramamine® Original Formula.

Another Quality Product Distributed by McKesson

One Post Street, San Francisco, CA 94104

Please visit us at www.sunmarkbrand.com

TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING.

KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION.

Package Label



Helps to prevent nausea, vomiting or dizziness associated with motion sickness



motion sickness

Original Formula

For children & adults
DIMENHYDRINATE
ANTIEMETIC



FAST ACTING

12 TABLETS 50 mg EACH

TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING.

KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION.

Lot No.:
Exp. Date:

*This product is not manufactured or distributed by Prestige Brands, Inc., owner of the registered trademark Dramamine® Original Formula.



Another Quality Product Distributed by McKesson
One Post Street, San Francisco, CA 94104
Money Back Guarantee
Please visit us at www.sunmarkbrand.com



PLD-B
FC001863

0 10939 53833 8

Uses for the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.

Warnings
Do not use for children under 2 years of age unless directed by a doctor.
Ask a doctor before use if you have
■ a breathing problem such as emphysema or chronic bronchitis ■ glaucoma
■ difficulty in urination due to an enlargement of the prostate gland
Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.
When using this product
■ marked drowsiness may occur ■ avoid alcoholic drinks
■ alcohol, sedatives, and tranquilizers may increase drowsiness
■ use caution when driving a motor vehicle or operating machinery
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions ■ to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity
adults and children 12 years 1 to 2 tablets every 4-6 hours; not to exceed 8 tablets in 24 hours, or as directed by a doctor
children 6 to under 12 years 1/2 to 1 tablet every 6-8 hours; not to exceed 3 tablets in 24 hours, or as directed by a doctor
children 2 to under 6 years 1/4 to 1/2 tablet every 6-8 hours; not to exceed 1-1/2 tablets in 24 hours, or as directed by a doctor

Other information ■ each tablet contains: calcium 30 mg ■ store at room temperature 20°-25°C (68°-77°F)

Inactive ingredients croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

Questions or comments? Call 1-877-753-3935 Monday-Friday 9AM-5PM EST



Sunmark Motion Sickness Tablet

MOTION SICKNESS ORIGINAL FORMULA

dimenhydrinate tablet

Product Information

Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:49348-070
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DIMENHYDRINATE (UNII: JB937PER5C) (DIPHENHYDRAMINE - UNII:8GTS82S83M)	DIMENHYDRINATE	50 mg

Inactive Ingredients

Ingredient Name	Strength
CROSCARMELOSE SODIUM (UNII: M28OL1HH48)	
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: L11K75P92J)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	

Product Characteristics

Color	WHITE	Score	2 pieces
Shape	ROUND	Size	9mm
Flavor		Imprint Code	1006;1006
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:49348-070-02	1 in 1 CARTON		
1		12 in 1 BLISTER PACK		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC MONOGRAPH FINAL	part336	06/13/2011	

